首页> 外国专利> Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method for stabilizing survivial of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method for producing the same, and gene encoding human monoclonal antibody and the gene introduced transformant

Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method for stabilizing survivial of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method for producing the same, and gene encoding human monoclonal antibody and the gene introduced transformant

机译:用于稳定移植的造血干细胞存活的组合物,用于获得该组合物的试剂盒,用于稳定移植的造血干细胞存活的方法,人单克隆抗体或人多克隆抗体及其生产方法,编码人单克隆抗体的基因和引入的基因转化子

摘要

[PROBLEMS] To stabilize the survival of transplanted hematopoietic stem cells by using HLA identical activated lymphocytes. [MEANS FOR RESOLVING PROBLEMS] HLA identical activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA identical activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for instance, prevention of survival failure of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 ml/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently once to 3 times in a week or once in 2 or 3 weeks.
机译:[问题]通过使用HLA相同的活化淋巴细胞来稳定移植的造血干细胞的存活。 [解决问题的方法]从外周血或脐带血分离的单核细胞中的HLA相同的活化淋巴细胞得以增殖和活化。分离并收集后,将HLA相同的活化淋巴细胞用作促进移植的造血干细胞存活的组合物的主要成分。所获得的组合物可广泛用于例如预防移植的造血干细胞的存活失败和促进其存活的疗法。尽管组合物的剂量根据患者的年龄,状况等而变化,但是人源化抗体以0.2至20ml / kg /天的剂量施用于包括人在内的哺乳动物。该组合物通过每天一次静脉内注射(单次给药或连续给药)或每周一次间歇性1-3次或在2或3周一次间歇性给药。

著录项

  • 公开/公告号AU2004245792B2

    专利类型

  • 公开/公告日2009-07-02

    原文格式PDF

  • 申请/专利权人 LYMPHOTEC INC.;

    申请/专利号AU20040245792

  • 申请日2004-05-26

  • 分类号C12N15/09;A61K35/14;A61K35/15;A61K35/17;A61K35/28;A61K35/51;A61K39/395;A61P31;A61P35;A61P37/04;C07K16;C07K16/18;C07K16/28;C12N1/15;C12N1/19;C12N1/21;C12N5/07;C12N5/0783;C12N5/0789;C12N5/10;C12N5/16;C12N5/24;C12N15/12;C12P21/08;

  • 国家 AU

  • 入库时间 2022-08-21 19:22:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号